Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Drugs in capsules, DNA and medicine, 3d rendering - Illustration
Payers see value in gene therapies, but capacity for mutiple products is limited. • Source: Shutterstock

More from Drug Pricing

More from Scrip